Globant AI Partnership Speeds Cancer Drug Insights 15x and Broadens Adyen Payment Integration
Globant launched a multi-agent AI platform with PharmaMar that delivers over 90% accuracy and speeds cancer drug discovery insights by 15-fold through analysis of 4,500+ documents to prioritize the top 10 treatment-indication combinations. It also expanded its partnership with Adyen to accelerate global payment integrations and modernize commerce ecosystems.
1. Strategic Oncology AI Collaboration
Globant and PharmaMar have formed an alliance to integrate Globant Enterprise AI into PharmaMar's R&D process, aiming to accelerate the discovery of marine-derived anti-cancer drugs. This collaboration focuses on leveraging AI to support data-driven decision-making across preclinical, clinical, regulatory and strategic functions within PharmaMar's oncology pipeline.
2. Multi-Agent AI System Capabilities
The multi-agent AI framework deploys over 20 specialized digital agents to process scientific, regulatory and clinical data, delivering over 90% retrieval accuracy and reducing time-to-insight by up to 15x. The platform analyzes more than 4,500 research documents to rank and prioritize the top 10 treatment-indication candidates from over 8,000 possibilities, simulating scenarios and enabling continuous self-improvement.
3. Expansion of Adyen Payment Partnership
In a separate development, Globant has broadened its partnership with Adyen to enhance payment ecosystems for global enterprises. The expanded agreement aims to speed integrations, support scalable commerce operations and modernize transaction platforms for clients across multiple industries.